Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-I7 in Healthy Volunteers
NCT02860715Phase 1Completed
- Sponsor
- Genexine
- Start
- Jul 2016
- Primary completion
- Jan 2017
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efineptakin alfa in lymphopenia (3 cohorts), sponsored by Genexine. Primary endpoint: Assessment of adverse events including laboratory abnormality at 4 weeks. Started Jul 2016; status: completed.
02
Drugs
efineptakin alfa
03
Conditions
lymphopenia
Beyond the preview
Go deeper on NCT02860715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02860715.